Welcome, Guest
Username: Password: Remember me
General
  • Page:
  • 1

TOPIC: BARDA

BARDA 20 Nov 2017 08:39 #10596

  • b767cpt
  • b767cpt's Avatar Topic Author
  • Offline
  • Gold Boarder
  • Gold Boarder
  • Posts: 279
  • Thank you received: 4
From Yahoo Summary MB

Cytori Reports Reduction in Fibrosis Parameters in Scar Study

Please Log in or Create an account to join the conversation.

BARDA 20 Nov 2017 08:45 #10597

  • franshei
  • franshei's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 789
  • Thank you received: 103
b7

I think the stock price will continue to move up before the RO deadline. All these PRs and efforts by Tiago Girao's company are not accidental. As long as the PPS moves up at this time, stockholders can sell the stock now and buy the RO at a bargain.

Please Log in or Create an account to join the conversation.

BARDA 20 Nov 2017 09:58 #10598

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3295
  • Thank you received: 1110

b767cpt wrote: From Yahoo Summary MB

Cytori Reports Reduction in Fibrosis Parameters in Scar Study


The full text Cytori Announcement:

BARDA Funded Preclinical Published in Stem Cell Research and Therapy

SAN DIEGO, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today the publication of preclinical data from a study using Cytori Cell Therapy™ in a model of fibrotic scar formation. This study was performed with support from the Biomedical Advanced Research and Development Authority (BARDA) as a component of the preclinical proof of concept data package incorporated into the FDA approved United States RELIEF Trial.

The publication describes a study in which Adipose Derived Regenerative Cells (ADRCs), the active component of Cytori Cell Therapy™, were injected into deep partial thickness wounds in a porcine model, considered the gold standard preclinical model of hypertrophic scarring. Six months after treatment, wounds that were treated with ADRCs showed reduction in parameters associated with hypertrophic scarring compared to control wounds. Parameters that were improved by treatment included skin hardness, organization, vascularity, and discoloration. Molecular analysis implicated the temporal modulation of Interleukin-6 expression, a key regulator of the inflammatory response, as a potential mediator of the effect.
The paper entitled “Autologous adipose-derived regenerative cell therapy modulates development of hypertrophic scarring in a red Duroc porcine model ” just published in the journal Stem Cell Research and Therapy and is now available online.
The findings from this preclinical study were incorporated into the design of the RELIEF clinical trial of Cytori Cell Therapy™ which is also funded by BARDA. The RELIEF trial will assess Cytori Cell Therapy in human patients with substantial thermal burn injury. In addition to assessment of early healing, the RELIEF trial will evaluate several scar-related parameters using approaches similar to those applied in this study.

“Fibrosis is a common factor in both burns and scleroderma.” said Dr. John Fraser, Chief Scientist at Cytori. “This preclinical study is consistent with a number of emerging studies indicating a beneficial effect of Cytori’s ADRC technology in fibrotic disease.”

The treatment of thermal burns remains a critical unmet medical need. Despite standard of care primarily consisting of dressings, skin grafts and skin substitutes, patients frequently suffer from pain, scarring, skin contracture and reduced range of motion. Hypertrophic scarring is characterized by raised, discolored, itchy and painful scars that are a common fibrotic consequence of deep-partial thickness burn injury.

Autologous cell therapies such as those offered by Cytori have the potential to improve the quality and rate of wound healing and reduce scarring. In a mass casualty event, the Government Accountability Office estimates that as many as 10,000 patients could require thermal burn care. The limited number of specialist surgeons and burn centers in the U.S. creates a public health need for a burn wound therapy that can be quickly and broadly applied by non-specialist medical personnel following such an event. Therefore, autologous Cytori’s Cell Therapy represents a novel medical countermeasure not only to address these challenges but also to promote wound healing and tissue repair and improve casualty care.

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

BARDA 20 Nov 2017 10:14 #10599

  • b767cpt
  • b767cpt's Avatar Topic Author
  • Offline
  • Gold Boarder
  • Gold Boarder
  • Posts: 279
  • Thank you received: 4
So what’s your opinion on this FAS?
Seems like press releases are flowing out now to entice buyers into the RO.
Have to admit, it’s becoming more enticing but still gunshy from the last RO disaster.

Please Log in or Create an account to join the conversation.

BARDA 20 Nov 2017 11:15 #10600

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3295
  • Thank you received: 1110

b767cpt wrote: So what’s your opinion on this FAS?
Seems like press releases are flowing out now to entice buyers into the RO.
Have to admit, it’s becoming more enticing but still gunshy from the last RO disaster.


Yes- it does look a bit like getting out everything possible to entice shareholders to sign up.

This is hardly news, since an abstract on the same pre-clinical was already presented in Chicago at the burn conference last May I believe. Just putting the same data in a scientific paper which was probably a BARDA pre-requisite and paid for by them.

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.094 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites